Trial Profile
Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms AINO
- 27 Mar 2019 Status changed from completed to discontinued. (Participants are no longer being examined. The results are published 2016 Anticancer Research 36: 6431-6438)
- 01 Dec 2016 Results published in the Anticancer Research
- 27 Apr 2016 Status changed from recruiting to completed.